Table 1 Baseline characteristics of patients with type B thymomas
From: Re-exploration of prognosis in type B thymomas: establishment of a predictive nomogram model
Variables | Overall | No progression | Progression | p-value |
|---|---|---|---|---|
Size (mm, median, quartile, md = 5) | 48.50 (35.00, 62.75) | 45.00 (32.00, 60.00) | 65.00 (50.00, 85.00) | < 0.001 |
Age (years, median, quartile, md = 0) | 49.00 (40.00, 58.00) | 50.00 (40.00, 58.25) | 44.00 (36.00, 51.00) | 0.026 |
Pathologic type (%, md = 0) | 0.342 | |||
Type B1 | 107 (30.3) | 89 (29.7) | 4 (13.8) | |
Type B2 | 134 (38.0) | 114 (38.0) | 13 (44.8) | |
Type B3 | 63 (17.8) | 55 (18.3) | 7 (24.1) | |
Type B thymoma with multiple histological subtypes coexisting | 49 (13.9) | 42 (14.0) | 5 (17.2) | |
Smoking (%, md = 0) | 0.267 | |||
No | 269 (76.2) | 230 (76.7) | 19 (65.5) | |
Yes | 84 (23.8) | 70 (23.3) | 10 (34.5) | |
Masaoka stage (%, md = 0) | < 0.001 | |||
Early stage | 246 (69.7) | 227 (75.7) | 2 (6.9) | |
Advanced stage | 107 (30.3) | 73 (24.3) | 27 (93.1) | |
Gender (%, md = 0) | 0.626 | |||
Female | 167 (47.3) | 144 (48.0) | 12 (41.4) | |
Male | 186 (52.7) | 156 (52.0) | 17 (58.6) | |
Myasthenia gravis (%, md = 0) | 0.794 | |||
No | 201 (56.9) | 173 (57.7) | 18 (62.1) | |
Yes | 152 (43.1) | 127 (42.3) | 11 (37.9) | |
Surgery approach (%, md = 10) | < 0.001 | |||
Minimal invasive | 231 (67.3) | 214 (71.6) | 5 (23.8) | |
Open | 112 (32.7) | 85 (28.4) | 16 (76.2) | |
R0 resection status (%, md = 2) | < 0.001 | |||
Yes | 329 (93.7) | 292 (97.3) | 14 (51.9) | |
No | 22 (6.3) | 8 (2.7) | 13 (48.1) | |
Radiotherapy (%, md = 22) | 0.001 | |||
No | 183 (55.3) | 173 (58.2) | 7 (24.1) | |
Yes | 148 (44.7) | 124 (41.8) | 22 (75.9) | |
Chemotherapy (%, md = 22) | < 0.001 | |||
No | 290 (87.6) | 268 (90.2) | 18 (62.1) | |
Yes | 41 (12.4) | 29 (9.8) | 11 (37.9) |